Skip to main content
. 2015 Sep 22;5:14310. doi: 10.1038/srep14310

Figure 7. Antitumor activity of C36L1 peptide in vivo.

Figure 7

(A) Antitumor activity of C36L1 at 10 mg/Kg peptide in subcutaneously grafted melanoma treated with peritumor injections of peptide. The tumor volume was documented during the treatment period (*p < 0.05, in relation to untreated control); (B) Survival kinetics of B16F10-Nex2 s.c. challenged animals, treated with C36L1 via peritumor route; (C) Therapeutic activity of bone marrow derived dendritic cells (bmDCs) stimulated with C36L1 and primed or unprimed with tumor cells lysate, transferred to 7 day-melanoma bearing mice. Arrest and even regression of metastatic nodules are shown (*p < 0.05, in relation to day-7 control); (D) Anti metastatic activity of C36L1 peptide in syngeneic murine melanoma model. Lungs were harvested for quantification of pulmonary metastatic nodules after peptide treatment. Representative images of the lungs are shown (*p < 0.05, in relation to untreated control).